Cullinan Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Recent price momentum is -28.2% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 12.3% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | -358.7% | Better than 4% |
| Net margin | -346.1% | Better than 4% |
| Return on equity | -44.0% | Better than 10% |
| Return on invested capital | -48.2% | Better than 6% |
Momentum C-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -59.0% | Better than 3% |
| 6-month return | -35.8% | Better than 14% |
| 12-month return (ex latest month) | 57.6% | Better than 87% |
| Distance below 52-week high | 61.7% | Better than 10% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 10.2x | Better than 94% |
| Debt to assets | 0.6% | Better than 95% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 282.5% | Better than 97% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 9.07
- Open
- 8.84
- Day range
- 8.80 - 9.46
- Avg price
- 8.96
- Volume
- 1.01M
- Turnover
- 9.06M
- Turnover ratei
- 2.07%
- Volume ratioi
- 0.85
- Amplitudei
- 7.22%
- 52-week rangei
- 8.47 - 23.19
Valuation
- P/Ei
- -2.65
- P/E (TTM)i
- -2.88
- P/Bi
- 2.05
- EPSi
- -3.36
- Book value / shi
- 4.33
- Net profit
- -218.13M
- Net assets
- 281.30M
Share structure
- Market cap
- 577.15M
- Float capi
- 433.63M
- Shares out
- 64.92M
- Float sharesi
- 48.78M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2021-01-08
61.7% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-1.48M net over the window
Short interest
- Shares short
- 7.93M
- % of floati
- 12.32%
- Days to coveri
- 13.33
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Cullinan Therapeutics (CGEM)?
Cullinan Therapeutics last traded at 8.89. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Cullinan Therapeutics's market cap?
About 577.15M.
What is the P/E ratio of Cullinan Therapeutics?
The trailing twelve-month P/E is -2.88. The Valuation tab shows it against the stock's own five-year range.
Does Cullinan Therapeutics pay a dividend?
Cullinan Therapeutics does not currently pay a regular dividend.
Is Cullinan Therapeutics a buy according to analysts?
The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 34.00, which implies 282.5% upside from the current price. This is not investment advice.
What is Cullinan Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Cullinan Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:38:37 · For reference only, not investment advice and not tailored to your situation.
Cullinan Therapeutics discussion 0 comments